Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | VCP | P55072 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
| ▸ | PNP | P00491 | 7/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | EDNRA | P25101 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | HBB | P68871 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganciclovir SCHEMBL2160505 | 1.00 | BLM (1.00) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10899902 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10481442 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL2433042 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10481436 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL1242615 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL25915 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL11093368 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10901635 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL11121521 | 0.99 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 81613 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144816-A1 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4748448-A2 | USE OF MARIBAVIR FOR THE TREATMENT OF AND TREATMENT REGIMENS THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-05-27 | — | — | EP | claimed |
| US-12637688-B2 | DNA construct for diagnosing and treating cancer | CNCURE BIOTECH INC. (KR) | 2026-05-26 | — | — | US | claimed |
| US-20260137669-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2026-05-21 | — | — | US | claimed |
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107010-A1 | MODULATION OF GENE EXPRESSION FOR GENE THERAPY | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12631653-B2 | Methods for diagnosing and treating uveitis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-19 | — | — | US | claimed |
| WO-2025136820-A9 | POLY-ANTIGEN CYTOKINE-RECEPTOR COMPLEXES (PACCS), COMPOSITIONS, AND METHODS OF USE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-05-15 | — | — | WO | claimed |
| EP-0066208-B1 | 9-(1,3-DIHYDROXY-2-PROPOXYMETHYL)-GUANINE AS ANTIVIRAL AGENT | SYNTEX (U.S.A.) INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0135713-A2 | Antiviral combinations | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-04-03 | — | — | EP | claimed |
| US-4507305-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1985-03-26 | — | — | US | claimed |
| EP-0119757-A2 | Guanine derivatives, compositions containing them, and their anti-viral use | SYNTEX (U.S.A.) INC. (US) | 1984-09-26 | — | — | EP | claimed |
| US-4462986-A | INTERFERON AND 9-((2-HYDROXY-1-(HYDROXYMETHYL)-ETHOXY)METHYL)GUANINE | ENS BIO LOGICALS, INC. (CA) | 1984-07-31 | — | — | US | claimed |
| EP-0109234-A1 | Compositions comprising interferon and their therapeutic use | SYNTEX (U.S.A.) INC. (US) | 1984-05-23 | — | — | EP | claimed |
| EP-0105486-A2 | 1-Monophosphate esters, 1,3-bisphosphate esters and cyclic phosphate esters of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine as antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1984-04-18 | — | — | EP | claimed |
| US-4423050-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1983-12-27 | — | — | US | claimed |
| EP-0066208-A1 | 9-(1,3-Dihydroxy-2-propoxymethyl)-guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1982-12-08 | — | — | EP | claimed |
| US-4355032-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1982-10-19 | — | — | US | claimed |